APOE determines cell type-specific pathological landscape of Alzheimer's disease
The apolipoprotein E (APOE) gene is the strongest genetic risk modifier for Alzheimer's disease (AD), with the APOE4 allele increasing risk and APOE2 decreasing it compared to the common APOE3 allele. Using single-nuclei RNA sequencing of the temporal cortex from APOE2 carriers, APOE3 homozygotes, and APOE4 carriers, we found that AD-associated transcriptomic changes were highly APOE genotype-dependent. Comparing AD with controls, APOE2 carriers showed upregulated synaptic and myelination-related pathways, preserving synapses and myelination at the protein level. Conversely, these pathways were downregulated in APOE3 homozygotes, resulting in reduced synaptic and myelination proteins. In APOE4 carriers, excitatory neurons displayed reduced synaptic pathways similar to APOE3, but oligodendrocytes showed upregulated myelination pathways like APOE2. However, their synaptic and myelination protein levels remained unchanged or increased. APOE4 carriers also showed increased pro-inflammatory signatures in microglia but reduced responses to amyloid-ß pathology. These findings reveal APOE genotype-specific molecular alterations in AD across cell types. Overall design: Single-nucleus RNA sequencing (snRNA-seq) was performed on temporal cortex samples from 60 cases. After quality control, 56 cases were retained for analysis, including 29 pathologically confirmed Alzheimer's disease (AD) cases and 27 controls. Within the AD group, 8 individuals were APOE2 carriers (E2/3), 10 were APOE3/3 homozygotes, and 11 were APOE4 carriers (E3/4 or E4/4). Among controls, 9 subjects were APOE2 carriers, 10 were APOE3/3 homozygotes, and 8 were APOE4 carriers